These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 35349107)

  • 1. Physician Perception of Disease Severity and Treatment Outcomes for Children and Adolescents with Atopic Dermatitis in Emerging Economies.
    Tang MBY; Fatani M; Wiggins S; Maspero J
    Dermatol Ther (Heidelb); 2022 Apr; 12(4):999-1013. PubMed ID: 35349107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis.
    Anderson P; Austin J; Lofland JH; Piercy J; Joish VN
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1571-1585. PubMed ID: 34268709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD.
    Paller AS; Gonzalez ME; Barnum S; Jaeger J; Shao L; Ozturk ZE; Korotzer A
    Arch Dermatol Res; 2024 Jul; 316(8):497. PubMed ID: 39080094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives.
    Eichenfield LF; Liu J; Marwaha S; Piercy J; Sturm D; Anderson P
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):685-696. PubMed ID: 38453811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.
    Simpson EL; Guttman-Yassky E; Margolis DJ; Feldman SR; Qureshi A; Hata T; Mastey V; Wei W; Eckert L; Chao J; Arnold RJG; Yu T; Vekeman F; Suárez-Fariñas M; Gadkari A
    JAMA Dermatol; 2018 Aug; 154(8):903-912. PubMed ID: 29971354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The disease burden of pediatric patients with atopic dermatitis in Japan.
    Ohya Y; Saeki H; Nawata H; Arima K; Inukai M; Rossi AB; Le-Bagousse-Bego G
    Pediatr Dermatol; 2023; 40(5):851-856. PubMed ID: 37581214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.
    Chopra R; Vakharia PP; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
    Br J Dermatol; 2017 Nov; 177(5):1316-1321. PubMed ID: 28485036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): Baseline treatment patterns and unmet needs assessment.
    Wei W; Ghorayeb E; Andria M; Walker V; Schnitzer J; Kennedy M; Chen Z; Belland A; White J; Silverberg JI
    Ann Allergy Asthma Immunol; 2019 Oct; 123(4):381-388.e2. PubMed ID: 31325566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.
    Kimball AB; Delevry D; Yang M; Chuang CC; Wang Z; Bégo-Le-Bagousse G; Martins B; Wu E; Shumel B; Wang J; Sierka D; Chao J; Strober B
    Dermatol Ther (Heidelb); 2023 Sep; 13(9):2107-2120. PubMed ID: 37552431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' and Caregivers' Experiences With Atopic Dermatitis-Related Burden, Medical Care, and Treatments in 8 Countries.
    Capozza K; Funk M; Hering M; Lang J; Merhand S; Manion R; Orevillo K; Picozza M; Proctor A; Schwennesen T; Begolka WS; Tullos K; Talent C; Tu M; Vastrup AS; Schwartz A
    J Allergy Clin Immunol Pract; 2023 Jan; 11(1):264-273.e1. PubMed ID: 36332836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
    Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of Moderate to Severe Atopic Dermatitis in Adults from France, Italy, and the UK: Patient-Reported Outcomes and Treatment Patterns.
    Kleyn CE; Barbarot S; Reed C; Losi S; von Arx LB; Robert C; Anderson P; Grond S; Costanzo A
    Dermatol Ther (Heidelb); 2022 Aug; 12(8):1947-1965. PubMed ID: 35913548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The humanistic and economic burden of atopic dermatitis among adults and adolescents in Saudi Arabia.
    Elezbawy B; Fasseeh AN; Fouly E; Esba LCA; Al Abdulkarim H; Al-Haddab M; Al-Sheikh A; Altawil E; Al Turaiki A; Eshmawi M; Hamadah I; Tannira M; Dalle H; Aderian S; Roshdy A; Jaheen A; Hamad T; Abaza S; Kaló Z
    J Med Econ; 2022; 25(1):1231-1239. PubMed ID: 36426726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study.
    Gkalpakiotis S; Kannenberg S; Kingo K; Nada HR; Rakhmatulina MR; Lesiak A; Nicolescu AC; Darlenski R; Masri A; Zhou L; Albuquerque T; Hammad S; Almasry I
    Dermatol Ther (Heidelb); 2024 May; 14(5):1173-1187. PubMed ID: 38702528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release of Cervical Muscle Tension Improves Psychological Stress and Symptoms of Moderate-to-Severe Atopic Dermatitis: a Case Series with 20 Patients.
    Hosono S; Fujita K; Nimura A; Akita K
    Dermatol Ther (Heidelb); 2022 Oct; 12(10):2383-2395. PubMed ID: 36129669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.
    Iannone M; Tonini G; Janowska A; Dini V; Romanelli M
    Curr Med Res Opin; 2021 Aug; 37(8):1295-1301. PubMed ID: 34027753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis.
    Fowler J; Sugarman J; Sher L; Zang C; Werth JL; Myers DE; Graham D; Marfo AA; Takiya L
    Dermatol Ther (Heidelb); 2023 Apr; 13(4):951-960. PubMed ID: 36811773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of synbiotic supplementation on children with atopic dermatitis: an observational prospective study.
    Ibáñez MD; Rodríguez Del Río P; González-Segura Alsina D; Villegas Iglesias V
    Eur J Pediatr; 2018 Dec; 177(12):1851-1858. PubMed ID: 30259127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burden of adult atopic dermatitis and unmet needs with existing therapies.
    Bacci ED; Correll JR; Pierce EJ; Atwater AR; Dawson Z; Begolka WS; Butler L
    J Dermatolog Treat; 2023 Dec; 34(1):2202288. PubMed ID: 37042571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.